Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1761-1765

  Di Iasio, Maria Grazia ^a   Addobbati, Riccardo ^b   Radillo, Oriano ^b   Voltan, Rebecca ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 181; MICRORNA 26A; MICRORNA 34A; NUTLIN 3; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; B CHRONIC LYMPHOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; HUMAN; HUMAN CELL; P53 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866736012     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9695-4     Document Type: Article

References (26)

1. Wierda W, O'Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078
2. Keating MJ, O'Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088
3. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13:23-31
4. Secchiero P, di Iasio MG, Gonelli A, Zauli G (2008) The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr Pharm Des 14:2100-2110
5. Wattel E, Preudhomme C, Hecquet B et al (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157
6. Secchiero P, Barbarotto E, Tiribelli M et al (2006) Functional integrity of the p53 mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122-4129
7. Kojima K, Konopleva M, McQueen T et al (2006) Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000
8. Saddler C, Ouillette P, Kujawski L et al (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:1584-1593
9. Secchiero P, Corallini F, Gonelli A et al (2007) Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61-69
10. Calin GA, Liu CG, Sevignani C et al (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101:11755-11760
11. Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801
12. Dijkstra MK, van Lom K, Tielemans D et al (2009) 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 23:625-627
13. Mraz M, Malinova K, Kotaskova J et al (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23:1159-1163
14. Zenz T, Mohr J, Eldering E et al (2009) miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113:3801-3808
15. Zenz T, Habe S, Denzel T et al (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597
16. Rossi S, Shimizu M, Barbarotto E et al (2010) microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116:945-952
17. Fabbri M, Bottoni A, Shimizu M et al (2011) Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305:59-67
18. Zauli G, Voltan R, di Iasio MG et al (2011) miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011 Mar 2. [Epub ahead of print]
19. Wang M, Tan L, Dijkstra M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13-20
20. Li S, Moffett HF, Lu J et al (2011) MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS ONE 6:e16956
21. Secchiero P, Melloni E, di Iasio MG et al (2009) Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 113:4300-4308
22. Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417-421
23. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135
24. Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403
25. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961-22964
26. Secchiero P, Sun D, De Vico AL et al (1997) Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 71:4571-4580